| GlaxoSmithKline AG - Infanrix DTPa-IPV+Hib, Pulver und Suspension zur Herstellung einer Injektionssuspension | | 00619 | | 01 | | Infanrix DTPa-IPV+Hib | | Pulver und Suspension zur Herstellung einer Injektionssuspension | | J07CA06 | | Diphtherie-Haemophilus-influenzae B-Pertussis-Poliomyelitis-Tetanus | | 29.09.1998 | | |
| | Composition | | I) DTPa-IPV: toxoidum diphtheriae min. 30 U.I., toxoidum tetani min. 40 U.I., toxoidum pertussis 25 µg, haemagglutininum filamentosum (B. pertussis) 25 µg, pertactinum (B. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (Stamm Mahoney) 40 U., virus poliomyelitis typus 2 inactivatus (Stamm MEF-1) 8 U., virus poliomyelitis typus 3 inactivatus (Stamm Saukett) 32 U., aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum corresp. natrium 1.8 mg, medium 199, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini B sulfas, polysorbatum 80, formaldehydum.
II) Hib: polysaccharida haemophili influenzae typus B 20752 conjugata cum toxoido tetani 10 µg, lactosum, pro praeparatione.
I) et II) corresp. DTPa-IPV + Hib: toxoidum diphtheriae min. 30 U.I., toxoidum tetani min. 40 U.I., toxoidum pertussis 25 µg, haemagglutininum filamentosum (B. pertussis) 25 µg, pertactinum (B. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (Stamm Mahoney) 40 U., virus poliomyelitis typus 2 inactivatus (Stamm MEF-1) 8 U., virus poliomyelitis typus 3 inactivatus (Stamm Saukett) 32 U., polysaccharida haemophili influenzae typus B 20752 conjugata cum toxoido tetani 10 µg, aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum corresp. natrium 1.8 mg, medium 199, lactosum, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini B sulfas, polysorbatum 80, formaldehydum. | | Packungsbestandteile | | II | | | Suspension injectable | | | | | | | | | BAG: Principe actif | Concentr. |
|---|
| Haemagglutinium Filamentosum (B. Pertussis) | 25 mcg | | Haemophilus Influenzae b Polysaccharida (Prp) | 10 mcg | | Pertactinum (B. Pertussis) | 8 mcg | | Toxoidum Diphtheriae | | | Toxoidum Pertussis | 25 mcg | | Toxoidum Tetani | | | Virus Poliomyelitis Typus 1 Inactivatum (Mahoney) | 40 UI | | Virus Poliomyelitis Typus 2 Inactivatum (Mef1) | 8 UI | | Virus Poliomyelitis Typus 3 Inactivatum (Saukett) | 32 UI |
| | | | Agents auxilliaires | Concentr. |
|---|
| Conjugata cum Toxoido Tetani | 10 µg | | Lactosum | | | Polysaccharida Haemophili Influenzae Typus B | 20752 |
| |
| I) et II) corresp. DTPa-IPV + Hib: toxoidum diphtheriae min. 30 U.I., toxoidum tetani min. 40 U.I., toxoidum pertussis 25 µg, haemagglutininum filamentosum (B. pertussis) 25 µg, pertactinum (B. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (Stamm Mahoney) 40 U., virus poliomyelitis typus 2 inactivatus (Stamm MEF-1) 8 U., virus poliomyelitis typus 3 inactivatus (Stamm Saukett) 32 U., polysaccharida haemophili influenzae typus B 20752 conjugata cum toxoido tetani 10 µg, aluminium ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum, lactosum, medium 199, residui: polysorbatum 80 et formaldehydum et neomycini sulfas et polymyxini B sulfas, aqua q.s. ad suspensionem pro 0.5 ml | | | | | | BAG: Principe actif | Concentr. |
|---|
| Haemagglutinium Filamentosum (B. Pertussis) | 25 mcg | | Haemophilus Influenzae b Polysaccharida (Prp) | 10 mcg | | Pertactinum (B. Pertussis) | 8 mcg | | Toxoidum Diphtheriae | | | Toxoidum Pertussis | 25 mcg | | Toxoidum Tetani | | | Virus Poliomyelitis Typus 1 Inactivatum (Mahoney) | 40 UI | | Virus Poliomyelitis Typus 2 Inactivatum (Mef1) | 8 UI | | Virus Poliomyelitis Typus 3 Inactivatum (Saukett) | 32 UI |
|
| I | | | Pulver und Suspension zur Herstellung einer Injektionssuspension | | | | | | | | Principe actif | Concentr. |
|---|
| Haemagglutininum Filamentosum (B. Pertussis) | 25µg / 0.5ml | | Pertactinum (B. Pertussis) | 8µg / 0.5ml | | Toxoidum Diphtheriae | 30U.I. / 0.5ml | | Toxoidum Pertussis | 25µg / 0.5ml | | Toxoidum Tetani | 40U.I. / 0.5ml | | Virus Poliomyelitis Typus 1 Inactivatus (Stamm Mahoney) | 40U. / 0.5ml | | Virus Poliomyelitis Typus 2 Inactivatus (Stamm Mef-1) | 8U. / 0.5ml | | Virus Poliomyelitis Typus 3 Inactivatus (Stamm Saukett) | 32U. / 0.5ml |
| | BAG: Principe actif | Concentr. |
|---|
| Haemagglutinium Filamentosum (B. Pertussis) | 25 mcg | | Haemophilus Influenzae b Polysaccharida (Prp) | 10 mcg | | Pertactinum (B. Pertussis) | 8 mcg | | Toxoidum Diphtheriae | | | Toxoidum Pertussis | 25 mcg | | Toxoidum Tetani | | | Virus Poliomyelitis Typus 1 Inactivatum (Mahoney) | 40 UI | | Virus Poliomyelitis Typus 2 Inactivatum (Mef1) | 8 UI | | Virus Poliomyelitis Typus 3 Inactivatum (Saukett) | 32 UI |
| | | | Agents auxilliaires | Concentr. |
|---|
| Alumine | 0.5mg / 0.5ml | | Medium | 199 | | Sodium Chlorure | | | Neomycine Sulfate | | | Polymyxine b Sulfate | |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 003 | | 34.32 | 53.75 | B | LS | Non |
|
|
